STOCK TITAN

[Form 4] Organon & Co. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Organon & Co. senior vice president and corporate controller Lynette Holzbaur reported equity compensation and related share activity. On March 31, 2026, she received grants of 75,125 and 41,736 Restricted Stock Units (RSUs), each RSU representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.

The filing also shows vesting of earlier RSU awards from March 31, 2023 and March 31, 2025, with the remaining one‑third of those grants converting into common shares. As part of the vesting, 1,212 and 1,914 shares of common stock were withheld at $5.70 per share to satisfy tax obligations, a non‑market disposition. Following these transactions, Holzbaur holds 26,402.427 shares of Organon common stock directly. The activity reflects routine compensation grants, vesting, and tax withholding rather than open‑market buying or selling.

Positive

  • None.

Negative

  • None.
Insider Holzbaur Lynette
Role SVP and Corporate Controller
Type Security Shares Price Value
Grant/Award Restricted Stock Units 75,125 $0.00 --
Grant/Award Restricted Stock Units 41,736 $0.00 --
Exercise Restricted Stock Units 4,252 $0.00 --
Exercise Restricted Stock Units 6,715 $0.00 --
Exercise Common Stock 4,252 $0.00 --
Tax Withholding Common Stock 1,212 $5.70 $7K
Exercise Common Stock 6,715 $0.00 --
Tax Withholding Common Stock 1,914 $5.70 $11K
Holdings After Transaction: Restricted Stock Units — 75,125 shares (Direct); Common Stock — 22,813.427 shares (Direct)
Footnotes (1)
  1. The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
New RSU grant 1 75,125 RSUs Granted March 31, 2026; vests in three equal installments 2027–2029
New RSU grant 2 41,736 RSUs Granted March 31, 2026; vests in three equal installments 2027–2029
RSU exercises 4,252 and 6,715 shares Common stock received from vesting of 2023 and 2025 RSU grants on March 31, 2026
Tax-withholding shares 1,212 and 1,914 shares Shares withheld at $5.70 per share to satisfy tax liabilities
Tax price reference $5.70 per share Closing market price on March 30, 2026 used for RSU plan calculations
Post-transaction holdings 26,402.427 shares Organon common stock directly owned after March 31, 2026 transactions
Restricted Stock Units financial
"the Restricted Stock Units ("RSU") were awarded."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest financial
"These RSUs will vest and become exercisable in three equal installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"each RSU representing a contingent right to receive one share"
tax liability financial
"Payment of exercise price or tax liability by delivering securities"
closing market price financial
"The price is the closing market price for Organon & Co. common stock"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Holzbaur Lynette

(Last)(First)(Middle)
C/O ORGANON & CO.
30 HUDSON STREET, FLOOR 33

(Street)
JERSEY CITY NEW JERSEY 07302

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP and Corporate Controller
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/31/2026M4,252A$022,813.427D
Common Stock03/31/2026F1,212D$5.7(1)21,601.427D
Common Stock03/31/2026M6,715A$028,316.427D
Common Stock03/31/2026F1,914D$5.7(1)26,402.427D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(2)03/31/2026A75,125 (2) (2)Common Stock75,125$075,125D
Restricted Stock Units(3)03/31/2026A41,736 (3) (3)Common Stock41,736$041,736D
Restricted Stock Units(4)03/31/2026M4,252 (5) (5)Common Stock4,252$00D
Restricted Stock Units(4)03/31/2026M6,715 (6) (6)Common Stock6,715$00D
Explanation of Responses:
1. The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
2. On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
3. On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
4. Each RSU represents a contingent right to receive one share of Organon common stock.
5. On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
6. On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
Remarks:
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Lynette Holzbaur04/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)